Several reports have shown that EGFR-driven NSCLC tumors are associated with low median TMB levels and a higher percentage of tumors with low (TPS 1 - 49%) or negative PD-L1 expression, resulting in a cold immune microenvironment and lack of response to ICI therapy (16, 22). This evidence concerns the gene EGFR and non-small cell lung carcinoma.